Background:Kallistatin is a glycoprotein found in human plasma. Kallistatin is mostly generated by the liver, with minor quantities made by the kidney, pancreas, heart, lung, and colon. In the tissue kallikrein – kinin system, kallistatin acts as a balancing agent. Kinins, kininogens, and kallikrein, kallistatin, and bradykinin receptors are all part of this system. When compensated disease sets in, kallistatin can be employed as a critical biomarker in detecting alcoholic liver disease early. In the early stages of liver disease, it is normally quiet and asymptomatic, but as it progresses to the symptomatic decompensated stage, it can cause serious consequences. The patient's prognosis is dismal, with portosystemic encephalopathy, variceael haemorrhage, and hepatocellular cancer. The current study was done to evaluate the use of Kallistatin as a non-invasive marker in the diagnosis of alcoholic liver disease (ALD), and to compare serum Kallistatin levels in alcoholic liver disease patients and healthy controls.